SEC 13F Intelligence

Kiniksa Pharmaceuticals Intern

CUSIP G5269C101

Kiniksa Pharmaceuticals Intern has 2 institutional holders in Filings Flow’s 13F database, together reporting 15.6K shares worth $24,471 as of Q1 2026. The largest reported holders are Birchview Capital, LP, Uniplan Investment Counsel, Inc., and Harbor Capital Advisors, Inc..

Institutional Holders
2
Q1 2026
Reported Value
$24,471
Ticker
unmapped
private placement or foreign
Quarters Tracked
9

Ownership Trend

Institutional holders
Q4 ’18: 37Q4 ’18Q1 ’19: 41Q2 ’19: 44Q2 ’19Q3 ’19: 38Q2 ’21: 85Q2 ’21Q4 ’21: 87Q4 ’22: 111Q4 ’22Q4 ’25: 1Q1 ’26: 2Q1 ’26filingsflow.com
Total reported value
Q4 ’18: $313MQ4 ’18Q1 ’19: $275MQ2 ’19: $186MQ2 ’19Q3 ’19: $119MQ2 ’21: $398MQ2 ’21Q4 ’21: $1.4BQ4 ’22: $238MQ4 ’22Q4 ’25: $889Q1 ’26: $24,471Q1 ’26filingsflow.com

Holders

Mixed quarters
Export to Excel
Manager% of PortfolioValueSharesQuarter
Birchview Capital, LP$176M AUM0.88%$1M30.0KQ3 2025OLDER
Uniplan Investment Counsel, Inc.$974M AUM0.00%$23,745493Q1 2026

Holdings are reported up to 45 days after quarter end. Share counts are as filed and not adjusted for stock splits.